
Home » GLAXOSMITHKLINE RECEIVES FDA APPROVAL FOR AVANDAMET
GLAXOSMITHKLINE RECEIVES FDA APPROVAL FOR AVANDAMET
GlaxoSmithKline has received FDA approval for Avandamet (rosiglitazone maleate and metformin HCl) for use as initial treatment of Type 2 diabetes as an adjunct to diet and exercise. Avandamet was previously approved as a second-line therapy -- it was indicated for use in patients who were uncontrolled on metformin monotherapy. Now, with this recent approval, physicians can start their Type 2 diabetes patients on Avandamet.
Avandamet is the only combination of a thiazolidinedione, rosiglitazone maleate (separately marketed as Avandia) and metformin HCl with approved use as initial therapy of Type 2 diabetes. The drug is indicated as an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes mellitus when treatment with dual rosiglitazone and metformin therapy is appropriate.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar
-
08Mar